Petros Pharmaceuticals, Inc. (PTPI)
NASDAQ: PTPI · Real-Time Price · USD
0.0691
-0.0169 (-19.65%)
At close: Mar 31, 2025, 4:00 PM
0.0710
+0.0019 (2.75%)
After-hours: Mar 31, 2025, 5:31 PM EDT
Petros Pharmaceuticals Revenue
Petros Pharmaceuticals had revenue of $1.58M in the quarter ending September 30, 2024, a decrease of -5.87%. This brings the company's revenue in the last twelve months to $4.02M, down -42.41% year-over-year. In the year 2023, Petros Pharmaceuticals had annual revenue of $5.82M, down -2.83%.
Revenue (ttm)
$4.02M
Revenue Growth
-42.41%
P/S Ratio
0.13
Revenue / Employee
$191,542
Employees
21
Market Cap
2.07M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
PTPI News
- 4 days ago - NextTrip Launches New Innovative Online Cruise Booking Platform NextTrip Cruise - Accesswire
- 11 days ago - Petros Pharmaceuticals to Partner with Renowned Big Data Provider to Enable Rx-to-OTC Switch Across Multiple Indications - Accesswire
- 4 weeks ago - NextTrip Strengthens Financial Position with the Conversion of $2.6 Million in Short-Term Debt to Restricted Equity Before its Fiscal Year-End - Accesswire
- 4 weeks ago - NextTrip and Blue Fysh Announce Strategic Partnership and Share Exchange Agreement to Drive Mutual Growth - Accesswire
- 4 weeks ago - Petros Pharmaceuticals' Proprietary Technology Demonstrates Positive Data in Pivotal Study - Accesswire
- 4 weeks ago - NextTrip Appoints John McMahon as Chief Operating Officer - Travel, Expands into Cruise Industry with Five Star Alliance - Accesswire
- 5 weeks ago - Petros Pharmaceuticals Announces Pricing of $9.6 Million Public Offering of Common Stock and Warrants - Accesswire
- 6 weeks ago - NextTrip Closes on 49% Stake in Five Star Alliance - Accesswire